Cargando…

Visual atrophy rating scales and amyloid PET status in an Alzheimer's disease clinical cohort

OBJECTIVES: Visual rating scales (VRS) are the quantification method closest to the approach used in routine clinical practice to assess brain atrophy. Previous studies have suggested that the medial temporal atrophy (MTA) rating scale is a reliable diagnostic marker for AD, equivalent to volumetric...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loreto, Flavia, Gontsarova, Anastassia, Scott, Gregory, Patel, Neva, Win, Zarni, Carswell, Christopher, Perry, Richard, Malhotra, Paresh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10109315/ https://www.ncbi.nlm.nih.gov/pubmed/36872523 http://dx.doi.org/10.1002/acn3.51749

Ejemplares similares

Using amyloid PET imaging to diagnose Alzheimer’s disease in patients with multiple sclerosis
por: Kolanko, Magdalena, et al.
Publicado: (2020)

Evaluating cognitive profiles of patients undergoing clinical amyloid-PET imaging
por: Loreto, Flavia, et al.
Publicado: (2021)

A predictive model using the mesoscopic architecture of the living brain to detect Alzheimer’s disease
por: Inglese, Marianna, et al.
Publicado: (2022)

Visual cognition in non-amnestic Alzheimer's disease: Relations to tau, amyloid, and cortical atrophy
por: Putcha, Deepti, et al.
Publicado: (2019)

Clinical, FDG and amyloid PET imaging in posterior cortical atrophy
por: Singh, Tarun D., et al.
Publicado: (2015)

FDG-PET versus Amyloid-PET Imaging for Diagnosis and Response Evaluation in Alzheimer’s Disease: Benefits and Pitfalls
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2023)

Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease
por: Sintini, Irene, et al.
Publicado: (2019)

Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease
por: Kerbler, Georg M, et al.
Publicado: (2014)

Amyloid PET imaging: applications beyond Alzheimer’s disease
por: Catafau, Ana M., et al.
Publicado: (2015)

Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer’s disease
por: Ossenkoppele, Rik, et al.
Publicado: (2020)

Usefulness of medial temporal lobe atrophy visual rating scale in detecting Alzheimer's disease: Preliminary study
por: Heo, Jae-Hyeok, et al.
Publicado: (2013)

Topographical Heterogeneity of Alzheimer’s Disease Based on MR Imaging, Tau PET, and Amyloid PET
por: Jeon, Seun, et al.
Publicado: (2019)

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
por: Alcolea, Daniel, et al.
Publicado: (2019)

Insensitivity of visual assessment of hippocampal atrophy in familial Alzheimer’s disease
por: Ringman, John Matthew, et al.
Publicado: (2010)

Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease
por: Insel, Philip S., et al.
Publicado: (2017)

Topographic Distribution of Amyloid-β, Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease
por: Therriault, Joseph, et al.
Publicado: (2021)

Cortical florbetapir-PET amyloid load in prodromal Alzheimer’s disease patients
por: Saint-Aubert, Laure, et al.
Publicado: (2013)

A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease
por: Nordberg, Agneta, et al.
Publicado: (2012)

Evaluation of choroidal thickness in prodromal Alzheimer’s disease defined by amyloid PET
por: López-de-Eguileta, Alicia, et al.
Publicado: (2020)

Asymmetric amyloid deposition in preclinical Alzheimer’s disease: A PET study
por: Kjeldsen, Pernille L., et al.
Publicado: (2022)

Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer’s disease
por: Kang, Min Su, et al.
Publicado: (2020)

[(18)F]THK-5351 PET Patterns in Patients With Alzheimer’s Disease and Negative Amyloid PET Findings
por: Oh, Minyoung, et al.
Publicado: (2022)

Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease()
por: Vandenberghe, Rik, et al.
Publicado: (2013)

Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease
por: Sehlin, Dag, et al.
Publicado: (2016)

Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer’s disease
por: Rodriguez-Vieitez, Elena, et al.
Publicado: (2016)

Dissociation of amyloid biomarkers in PET and CSF in Alzheimer’s disease: a case report
por: Schroeter, Matthias L., et al.
Publicado: (2015)

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
por: Palmqvist, Sebastian, et al.
Publicado: (2015)

Efficacy and Limitations of rCBF-SPECT in the Diagnosis of Alzheimer’s Disease With Amyloid-PET
por: Takahashi, Miwako, et al.
Publicado: (2019)

Ganglion cell layer thinning in prodromal Alzheimer's disease defined by amyloid PET
por: López-de-Eguileta, Alicia, et al.
Publicado: (2019)

Is tau in the absence of amyloid on the Alzheimer’s continuum?: A study of discordant PET positivity
por: Weigand, Alexandra J, et al.
Publicado: (2019)

Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease
por: Amadoru, Sanka, et al.
Publicado: (2020)

Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study
por: Lopes Alves, Isadora, et al.
Publicado: (2020)

PET molecular imaging for pathophysiological visualization in Alzheimer’s disease
por: Wang, Jing, et al.
Publicado: (2022)

Amyloid PET, FDG-PET or MRI? - the power of different imaging biomarkers to detect progression of early Alzheimer’s disease
por: Ortner, Marion, et al.
Publicado: (2019)

Amyloid-β, p-tau and reactive microglia are pathological correlates of MRI cortical atrophy in Alzheimer’s disease
por: Frigerio, Irene, et al.
Publicado: (2021)

New approaches for the quantification and targeting of noradrenergic dysfunction in Alzheimer's disease
por: David, Michael, et al.
Publicado: (2022)

Increased mtDNA mutations with aging promotes amyloid accumulation and brain atrophy in the APP/Ld transgenic mouse model of Alzheimer’s disease
por: Kukreja, Lokesh, et al.
Publicado: (2014)

Systematic Evaluation of Kinetics and Distribution of Muscle and Lymph Node Activation Measured by (18)F-FDG- and (11)C-PBR28-PET/CT Imaging, and Whole Blood and Muscle Transcriptomics After Immunization of Healthy Humans With Adjuvanted and Unadjuvanted Vaccines
por: Win, Zarni, et al.
Publicado: (2021)

PET amyloid in normal aging: direct comparison of visual and automatic processing methods
por: Haller, Sven, et al.
Publicado: (2020)

Visual assessment of posterior atrophy development of a MRI rating scale
por: Koedam, Esther L. G. E., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_dm18vjjhjqlnoi40gskc0fpqvi